Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Pacira Pharmaceuticals (PCRX) Data 'Increases Takeout Valuation' - Mizuho
March 1, 2017 10:30 AM ESTShares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study hit both of its co-primary endpoints (demonstrating statistically significant benefits for greater pain reduction (p=0.0381) and lower opioid utilization (p=0.0048). Secondary endpoints such as... More
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
March 1, 2017 7:31 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.09, $0.08 better than the analyst estimate of $0.01. Revenue for the quarter came in at $72.9 million versus the consensus estimate of $73.07 million.
We made important progress in 2016 advancing our three-part EXPAREL growth strategy and setting the stage for continued success, said Dave Stack, chief executive officer and chairman of Pacira. We have multiple, major milestones on track for 2017, including the positive topline results reported today from our Phase 4 study in TKA. Our collaboration with DePuy Synthes is off to a strong start and will allow us to... More
